Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Genitourinary 7Other hematologic neoplasm 6Lymphoid 5Breast 4Head & Neck 3Thoracic 2Sarcoma 2Plasma cell 2Other solid neoplasm 2Myeloid 2Gynecologic 2Dermatologic 2CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 610Radiotherapy 387Bevacizumab 253Magnetic Resonance Spectroscopy 202Cyclophosphamide 177Carboplatin 159Radiosurgery 145Etoposide 132Radiation 120Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 81Lomustine 80Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Reverse Transcriptase Polymerase Chain Reaction × CNS × Clear all
NCT00498927 2016-02-29

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
47 enrolled 7 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡